COMP <GO>
BRKR vs LLY // REVENUE GROWTH (YOY)
Bruker Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BRKR 2
— LLY 13
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $57.07 (-7.95%) • MKT CAP: $9.45B
revenue-growth
2.10%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRKR VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRKR | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | 83.64% | -37.74 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | 32.36% | -31.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 75.7x | 36.4x | +39.28 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 0.46% | 2.30% | -1.84 | LLY | /fcf-yield <GO> |
| Operating Margin | 2.00% | 40.21% | -38.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 31.90% | -32.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 2.10% | 45.51% | -43.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 0.49% | -0.25 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 9.29 | -6.48 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 77.9 | -32.34 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.51 | +0.46 | BRKR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 26.3x | -4.25 | BRKR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.45B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRKR REV | LLY REV | BRKR GROSS % | LLY GROSS % | BRKR FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.44B | $65.18B | 45.9% | 83.0% | $43.3M | $16.81B |
| FY 2024 | $3.37B | $45.04B | 49.0% | 81.3% | $136.0M | $8.82B |
| FY 2023 | $2.96B | $34.12B | 44.0% | 79.3% | $216.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRKR // BETA 0.97
LLY // BETA 0.51